January 21, 2026

What Is a Biotech Investor Presentation? What is it Not? And Which Presentation Theories Apply?

What is an investor presentation and what is it not?

A public biotech’s investor presentation (often called the corporate deck) is the single most important document management uses to articulate its investment case – why the company exists, why it matters, and why an investor should own the company’s stock now.

It is the deck used in one-on-one investor meetings, on non-deal roadshows, and at healthcare investor conferences. It is also usually downloadable on the company’s IR website.

The intended audience is broad but sophisticated: institutional investors, retail investors, sell-side analysts, and bankers – collectively, your financial ecosystem.

What it is not is an exhaustive corporate history. It is not a business development deck for presentations to Big Pharma. And it is also not a media primer for journalists. Over the years, I have seen companies attempt to use a single deck for all three purposes (business development, media and IR) and it never works. The result is always bloated, unfocused, and ineffective.

A good biotech investor presentation should be able to stand on its own without a talk track – even though it is usually delivered live by the CEO or CFO.

Investor presentation developers should assume that the reader has a reasonable scientific understanding. Some simplification is necessary to make a story accessible to both generalists and specialists, but excessive “dumbing down” risks being misleading – or worse, insulting.

How long should a biotech Investor presentation be?

In practice, 25-30 slides are the sweet spot. The exact number typically depends on whether you use divider slides.

The logic is straightforward:

• Biotech slides are information-dense and typically take 1-2 minutes each to present.
• Investor meetings usually run 25–30 minutes.
• You should always leave 5–10 minutes for Q&A.

If you cannot clearly articulate your investment case within that framework, the problem is not the slide count – it is the story.

In the remainder of this blog, I want to explore some of the presentation “theories” frequently cited in connection with investor decks and weigh them against my own real-world experience.

Presentation theories and their applicability:

1. The 10/20/30 Rule

Popularized by Guy Kawasaki, this rule suggests that presentations should:

• Have no more than 10 slides.
• Be delivered in 20 minutes.
• Use a minimum 30-point font.

The intention is sound: focus, simplicity, and legibility.

Reality: Biotech investor presentations are too complex – and investors too inquisitive – for a 10-slide limit to be realistic. Twenty minutes, however, is about right in terms of duration, assuming you want to leave five to ten minutes for Q&A.

2. The 5x5x5 Rule

This is an unattributed guideline suggesting:

• No more than five words per line on a slide.
• No more than five lines per slide.
• No more than five text-heavy slides in a row.

In theory, this encourages brevity and forces presenters to speak rather than read.

Reality: Five words per line becomes impossible when precision matters. Try accurately describing clinical data without risking misinterpretation. Five lines per slide, however, is a sensible constraint. And breaking up text-heavy slides with figures, charts, and graphics is essential to maintaining attention.

3. The Data-Ink Ratio Theory

Introduced by Edward Tufte, this concept asks how much of a visual actually conveys data versus decoration. The goal is to maximize signal and minimize noise – no gratuitous 3D charts, heavy borders, or ornamental graphics.

Reality: This is one theory I fully subscribe to. As a former equity analyst, I reviewed hundreds of decks a month. In that environment, clarity is everything. Superfluous graphics do not help. In fact, they often suggest there isn’t much to say.

When building slides, always ask: Is this necessary? How much of the “ink” on the page is actually advancing the investment case? The higher the proportion, the better – without tipping into amateur-looking minimalism.

4. Minto Pyramids

Barbara Minto’s top-down communication framework places a conclusion first, followed by grouped, supporting arguments, and then evidence.

Reality: Minto Pyramids are excellent for structuring thinking and for building decks from scratch. In practice, most biotech investor presentations follow a well-worn structure that already approximates this logic. Also, applying Minto’s framework rigorously (essentially producing a draft of the deck before you create the deck) often doubles the work without materially improving the outcome – unless, that is, you are starting from a blank page.

5. The Audience Memory Curve Theory

This theory observes that audiences remember information best at the beginning and end of a presentation – and least in the middle.

Reality: This is the framework I believe in most. It leads to a simple but powerful discipline:

• Tell them what you’re going to say.
• Say it.
• Remind them what you said.

Because of this – and the data behind it – I strongly encourage companies to bookend their investor presentations with an identical Investment Summary. Repetition, done correctly, is a feature – not a flaw.